Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002;62(14):2007-12.
doi: 10.2165/00003495-200262140-00001.

The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications

Affiliations
Review

The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications

Toomas Podar et al. Drugs. 2002.

Abstract

Evidence suggests that ACE inhibitors can be advantageous for prevention and halting progression of both micro- and macrovascular complications in patients with diabetes mellitus. ACE inhibitors are useful antihypertensive agents in both type 1 and type 2 diabetes; however, ACE inhibitor therapy often needs to be supplemented with calcium channel antagonists, beta-blockers or diuretics to achieve good blood pressure control. ACE inhibitors are also indicated in non-hypertensive patients with type 1 and type 2 diabetes who have micro- or macroalbuminuria. The effect of ACE inhibitors in halting the development and progression of retinopathy and, potentially, neuropathy needs further proof in large-scale studies. More recently, angiotensin II receptor antagonists are emerging as drugs with the potential to be successfully included in the management of diabetic complications, especially when ACE inhibitors are not suitable because of adverse effects.

PubMed Disclaimer

References

    1. Lancet. 1998 Jan 3;351(9095):28-31 - PubMed
    1. Lancet. 2000 Jan 22;355(9200):253-9 - PubMed
    1. Ann Intern Med. 1999 Nov 2;131(9):660-7 - PubMed
    1. Diabet Med. 1995 Apr;12(4):307-9 - PubMed
    1. Lancet. 2002 Mar 23;359(9311):1004-10 - PubMed

Publication types

MeSH terms

Substances